Y Ganor-Paz1,2, Y Friedler-Mashiach3, Y Ghetler3,4, A Hershko-Klement3,4, A Berkovitz3,4, O Gonen3,4, A Shulman3,4, A Wiser3,4. 1. Department of Obstetrics and Gynecology, Meir Medical Center, 59 Tshernichovsky Street, Kfar Saba, Israel. yael.ganor@gmail.com. 2. Tel Aviv University, Tel Aviv, Israel. yael.ganor@gmail.com. 3. Department of Obstetrics and Gynecology, Meir Medical Center, 59 Tshernichovsky Street, Kfar Saba, Israel. 4. Tel Aviv University, Tel Aviv, Israel.
Abstract
PURPOSE: To evaluate whether high LH/FSH ratio has a clinical impact on patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) with GnRH-agonist/antagonist protocols or in vitro maturation (IVM) treatments. METHODS: We retrospectively reviewed all PCOS patients with day 3 LH/FSH ratio ≥1.5 who underwent IVF or IVM. The main outcomes measures were embryo quality and pregnancy rate. RESULTS: A total of 75 cycles were included. Among these, 44 patients underwent long agonist protocol, 16 antagonist protocol and 15 IVM. Age, basal LH and FSH levels, as well as duration of infertility were comparable for all groups. The LH level on the day of hCG administration was significantly lower in the antagonist group (0.9 IU/ml) compared to the long agonist group (1.4 IU/ml, p = 0.01). There was no difference in pregnancy rates among the groups: 27.2 % in the long agonist group, 37.5 % in the antagonist group and 26.6 % among the IVM patients. CONCLUSIONS: High LH/FSH ratio had no adverse effect on pregnancy rates in all three treatment modes.
PURPOSE: To evaluate whether high LH/FSH ratio has a clinical impact on patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) with GnRH-agonist/antagonist protocols or in vitro maturation (IVM) treatments. METHODS: We retrospectively reviewed all PCOSpatients with day 3 LH/FSH ratio ≥1.5 who underwent IVF or IVM. The main outcomes measures were embryo quality and pregnancy rate. RESULTS: A total of 75 cycles were included. Among these, 44 patients underwent long agonist protocol, 16 antagonist protocol and 15 IVM. Age, basal LH and FSH levels, as well as duration of infertility were comparable for all groups. The LH level on the day of hCG administration was significantly lower in the antagonist group (0.9 IU/ml) compared to the long agonist group (1.4 IU/ml, p = 0.01). There was no difference in pregnancy rates among the groups: 27.2 % in the long agonist group, 37.5 % in the antagonist group and 26.6 % among the IVM patients. CONCLUSIONS: High LH/FSH ratio had no adverse effect on pregnancy rates in all three treatment modes.
Authors: B C Tarlatzis; B C Fauser; E M Kolibianakis; K Diedrich; L Rombauts; P Devroey Journal: Hum Reprod Update Date: 2006-03-27 Impact factor: 15.610
Authors: A E Taylor; B McCourt; K A Martin; E J Anderson; J M Adams; D Schoenfeld; J E Hall Journal: J Clin Endocrinol Metab Date: 1997-07 Impact factor: 5.958
Authors: Tim J Child; Simon J Phillips; Ahmad Kamal Abdul-Jalil; Bulent Gulekli; Seang Lin Tan Journal: Obstet Gynecol Date: 2002-10 Impact factor: 7.661
Authors: B C Tarlatzis; G Grimbizis; F Pournaropoulos; J Bontis; S Lagos; E Spanos; S Mantalenakis Journal: Hum Reprod Date: 1995-10 Impact factor: 6.918
Authors: Min Hye Choi; Sun Hee Lee; Hye Ok Kim; Sun Hwa Cha; Jin Young Kim; Kwang Moon Yang; In Ok Song; Mi Kyoung Koong; Inn Soo Kang; Chan Woo Park Journal: Clin Exp Reprod Med Date: 2012-12-31